比卡鲁胺与氟他胺治疗晚期去势抵抗性前列腺癌的对比研究

摘要

目的:探讨比卡鲁胺与氟他胺分别治疗晚期去势抵抗性前列腺癌的疗效.方法:选取2012年12月-2016年12月松滋市人民医院收治的晚期去势抵抗性前列腺癌患者76例作为研究对象,以随机数字表法分为甲组和乙组,每组38例.甲组患者给予比卡鲁胺治疗,乙组患者给予氟他胺治疗.观察两组患者的临床症状、血清前列腺特异性抗原水平、不良反应发生情况.结果:治疗后22、30、40个月,甲组患者血清前列腺特异性抗原水平明显低于乙组,差异均有统计学意义(P<0.05);甲组患者不良反应发生率为31.58%(12/38),明显低于乙组的60.53%(23/38),差异有统计学意义(P<0.05).结论:比卡鲁胺治疗晚期去势抵抗性前列腺癌的疗效显著,能明显控制前列腺癌的疾病进展,降低血清前列腺特异性抗原水平,且不良反应较少.%OBJECTIVE:To probe into the comparison on efficacy of bicalutamide and flutamide in treatment of advanced castration-resistant prostate cancer(CRPC). METHODS:76 patients with advanced CRPC admitted into People`s Hospital of Songzi from Dec. 2012 to Dec. 2016 were selected to be divided into group A and group B via the random number table, with 38 cases in each. Patients in group A were given bicalutamide, while the group B received flutamide. The clinical symptoms, serum prostate specific antigen level and incidence of adverse drug reactions of two groups were observed. RESULTS:After treatment of 22, 30 and 40 months, the serum prostate specific antigen level of group A was significantly lower than that of group B, with statistically significant difference(P<0.05). The incidence of adverse drug reactions in group A was 31.58%(12/38), significantly lower than that of group B [60.53%(23/38)], with statistically significant difference(P<0.05). CONCLUSIONS:The efficacy of bicalutamide in treatment of advanced CRPC is remarkable, which can effectively control the disease progression of prostate cancer, reduce the serum prostate specific antigen level with few adverse drug reactions.